Injection of polymethylmethacrylate (PMMA) cement into vertebral bodies (VBs), i.e.. percutaneous transpedicular vertebroplasty (PVP), is being used with increasing frequency to treat painful VB compression fractures (VCFs). 3, 5 What type of cement is best suited for vertebroplasty is unknown, and there is no cement specifically approved by the FDA for use in vertebroplasty. Cements approved for other applications are commonly altered for use in vertebroplasty by adding various opacifiers designed to increase cement fluoroscopic visibility 5 (thus preventing extravagation) and by increasing the monomer-to-polymer ratio to decrease viscosity, increase working time, and facilitate injection through a cannula. 4, 5 The effect of such alterations on stabilizing osteoporotic VCFs is unknown.
Introduction
Injection of polymethylmethacrylate (PMMA) cement into vertebral bodies (VBs), i.e.. percutaneous transpedicular vertebroplasty (PVP), is being used with increasing frequency to treat painful VB compression fractures (VCFs). 3, 5 What type of cement is best suited for vertebroplasty is unknown, and there is no cement specifically approved by the FDA for use in vertebroplasty. Cements approved for other applications are commonly altered for use in vertebroplasty by adding various opacifiers designed to increase cement fluoroscopic visibility 5 (thus preventing extravagation) and by increasing the monomer-to-polymer ratio to decrease viscosity, increase working time, and facilitate injection through a cannula. 4, 5 The effect of such alterations on stabilizing osteoporotic VCFs is unknown.
Other types of injectable materials are also being proposed for use in PVP. 2, 6 The osteoconductivity and absent exotherm of hydroxyapatite-forming materials make them an attractive alternative to PMMA cements. One such material, BoneSource® (Stryker-Howmedica-Osteonics, Rutherford, NJ), has been proposed for possible use in vertebroplasty. Thus, the purpose of this study was to measure the biomechanical effectiveness of three cements in providing internal support to osteoporotic vertebrae with simulated VCFs.
Materials and Methods
Six VBs (T8-T10 and L1-L4) from each of 10 fresh spines were harvested from female cadavers (age, 81 ± 12 years), and L2-L4 were evaluated for osteoporosis (average t-score, -3.8 ± 1.1; average bone mineral density, 0.75 ± 0.15 g/cm 2 ) via the DEXA method. The vertebrae were disarticulated, their discs were excised, and the posterior elements were removed to facilitate mechanical testing.
With a Latin square design, the VBs were segregated into two groups of three vertebral levels: the thoracic group (T8-T10) and the lumbar group (L2-L4). Within each group, the VBs were assigned to one of three treatments: SP, Simplex P® (Stryker-Howmedica-Osteonics, Rutherford, NJ); F2, Simplex P® formulated in a manner consistent with the practice of vertebroplasty; and BS, BoneSource® (Stryker-Howmedica-Osteonics). Each thawed VB was floated in its sealed plastic bag in a water bath (37°C) for at least 1 hour before mechanical testing. Just before testing VB heights were measured. Each VB was preloaded and tested in axial compression. 7 Initial strength was defined as the peak load (load at failure), and stiffness was defined as the slope of the force versus deformation curve between 448 and 1112 N. 7 For VBs in the thoracic group, a bolus of 2 cc of the appropriate material was injected through each needle into the interior of the VB, resulting in a total interior fill of 4 cc. For VBs in the lumbar group, a bolus of 3 cc was injected through each pedicle for a total fill of 6 cc. VBs in the SP group were injected with Simplex P® mixed as directed by the manufacturer. VBs in the F2 group were injected with Simplex P®, modified by adding a 20-mL vial of monomer liquid to 40 g of powder that contained 28 g of PMMA and 12 g of BaSO4, thus yielding a cement with a 30% BaSO4 content by weight and a monomer-to-powder ratio of 0.71mL/g. VBs in the BS group were injected with a mixture of a 10-g vial of BoneSource® powder and a 5-g vial of methylcellulose solution to facilitate injection through the cannulae. BoneSource® is radiopaque; no additional opacification was required.
After injection, each VB was returned to the bath for 24 hours to simulate physiologic conditions and allow the cements to cure; each was then recompressed per the initial crush protocol and stiffness was recalculated. Strength after repair was defined as the maximum load, which occurred within the first 6 mm of compression. On average, 6 mm equaled 25% compression. 6 We used a repeated measures ANOVA to analyze the effect of treatment on VB stiffness and strength. The factors were treatment cement (SP, F2, BS) and condition (initial versus after treatment). A Tukey's post hoc comparison test was conducted to determine if differences were significant (i.e., p < 0.05).
Results
Although neither modified cement (F2 or BS) augmented VB strength (Tables 1 and 2 ) to the level achieved by Simplex P® (SP), they did restore VB strength to initial levels and beyond. Furthermore, posttreatment stiffness values for all cements were similar. Both altered cements (F2 and BS) exhibited injectability similar to that of Simplex P®. 4.0 ± 0.3 4.4 ± 0.3 3.8 ± 0.3 # (n = 9); + (n = 10); all values aremean ± SEM Discussion Both altered cements restored VB strength but not stiffness. Similar results were reported for Cranioplastic™, 1 which has been used clinically for many years with positive outcomes. 5 The use of methylcellulose solution to mix BoneSource® provided a cement that was easily injected into the VB via 11-gauge cannulae. The BoneSource® mixture was somewhat more viscous than Simplex P® and required slightly more effort than either Simplex P® or F2, although injection pressure was not measured. Previous studies have reported difficulty in injecting apatite cements. 6 Similar difficulties were experienced in pilot work to the current study when BoneSource® was mixed with sterile water, as recommended in the product insert. Hydroxyapatite materials have the potential advantage of being osteoconductive and not exothermic.
These results suggest that the altered cements may provide sufficient mechanical augmentation and may be candidates for use clinically in PVP.
